Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.

Created on 17 Jul 2026

Authors

Zeina Nahleh, Catherine M Alfano, Mark R Somerfield, Janie M Lee, Tina J Hieken, Allison Magnuson, Ruta D Rao, Helen K Chew, Stephen K L Chia, Brittany E Harvey, Ellen Landsberger, Bora Lim, Sitna Ali Mwanzi, Heather A Parsons, Debra Patt, Jasmine S Sukumar, Hyuna Sung, Gustavo Werutsky, Maryam Lustberg

Published in

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Pages 101200JCO2601700. Jul 16, 2026. Epub Jul 16, 2026.

Abstract

To offer clinicians recommendations concerning breast cancer follow-up and surveillance after primary treatment.
ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process.
One randomized controlled trial (RCT) was identified and formed the evidentiary basis for the surveillance mammography guideline recommendation. No RCTs were identified that evaluated different follow-up approaches by risk of relapse in patients treated for early-stage breast cancer. Given the dearth of evidence identified in the systematic review of the literature, formal modified Delphi consensus-based recommendations were generated.
The guideline offers recommendations on the role of a risk-based approach to the frequency and intensity of follow-up among patients with breast cancer in the adjuvant setting. Regular history, physical examination, and mammography are recommended for breast cancer follow-up. Either virtual or in-person visits can be offered. Certain patients at high risk of cancer recurrence warrant closer surveillance, such as those patients with locally advanced disease or residual disease following neoadjuvant chemotherapy. Recommendations on the use of blood-based biomarkers and supplemental imaging are provided. Guideline recommendations will be updated once additional evidence-based tools become available to better individualize surveillance.Additional information is available at www.ascopubs.org/topics/asco-guidelines/breast-cancer.

PMID:
42462191
Bibliographic data and abstract were imported from PubMed on 17 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement